$CRMD News

CorMedix: Durable Commercial Base, But 2027 Is The Real Test

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

CorMedix Inc. Q2 2026 Earnings Call Summary

Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ...

CorMedix Q2 Earnings Call Highlights

CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Stock Jumps on Strong DefenCath Sales

Full Transcript: Cormedix Q2 2026 Earnings Call

Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est

U.S. District Court Granted Preliminary Approval Of CorMedix Derivative Settlement On July 24; Final Hearing Set For September 23

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $13

CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook

The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why

CorMedix Inc. (CRMD) Reports Q1 2026 Results

U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation